256 related articles for article (PubMed ID: 15087069)
1. Juvenile myelomonocytic leukemia.
Emanuel PD
Curr Hematol Rep; 2004 May; 3(3):203-9. PubMed ID: 15087069
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
Koike K; Matsuda K
Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Flotho C; Steinemann D; Mullighan CG; Neale G; Mayer K; Kratz CP; Schlegelberger B; Downing JR; Niemeyer CM
Oncogene; 2007 Aug; 26(39):5816-21. PubMed ID: 17353900
[TBL] [Abstract][Full Text] [Related]
4. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay.
Tanaka M; Takahashi Y; Xu Y; Yoshida N; Yoshimi A; Villalobos IB; Hama A; Nishio N; Hidaka H; Wang Y; Yagasaki H; Kojima S
Leuk Res; 2008 Jul; 32(7):1036-42. PubMed ID: 18164384
[TBL] [Abstract][Full Text] [Related]
5. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment of juvenile myelomonocytic leukemia(JMML)].
Adachi S; Nakahata T
Nihon Rinsho; 2001 Dec; 59(12):2401-6. PubMed ID: 11766346
[TBL] [Abstract][Full Text] [Related]
7. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.
Gratias EJ; Liu YL; Meleth S; Castleberry RP; Emanuel PD
Pediatr Blood Cancer; 2005 Feb; 44(2):142-6. PubMed ID: 15390271
[TBL] [Abstract][Full Text] [Related]
8. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.
Emanuel PD; Snyder RC; Wiley T; Gopurala B; Castleberry RP
Blood; 2000 Jan; 95(2):639-45. PubMed ID: 10627474
[TBL] [Abstract][Full Text] [Related]
10. Juvenile myelomonocytic leukemia.
Satwani P; Kahn J; Dvorak CC
Pediatr Clin North Am; 2015 Feb; 62(1):95-106. PubMed ID: 25435114
[TBL] [Abstract][Full Text] [Related]
11. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
[TBL] [Abstract][Full Text] [Related]
12. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
Chan RJ; Leedy MB; Munugalavadla V; Voorhorst CS; Li Y; Yu M; Kapur R
Blood; 2005 May; 105(9):3737-42. PubMed ID: 15644411
[TBL] [Abstract][Full Text] [Related]
13. Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Metzner A; Horstmann MA; Fehse B; Ortmeyer G; Niemeyer CM; Stocking C; Mayr GW; Jücker M
Gene Ther; 2007 Apr; 14(8):699-703. PubMed ID: 17268534
[TBL] [Abstract][Full Text] [Related]
14. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
Niemeyer CM; Kratz CP
Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
[TBL] [Abstract][Full Text] [Related]
15. RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro.
Ohtsuka Y; Manabe A; Kawasaki H; Hasegawa D; Zaike Y; Watanabe S; Tanizawa T; Nakahata T; Tsuji K
Blood; 2005 Nov; 106(9):3134-41. PubMed ID: 16046524
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Tartaglia M; Niemeyer CM; Fragale A; Song X; Buechner J; Jung A; Hählen K; Hasle H; Licht JD; Gelb BD
Nat Genet; 2003 Jun; 34(2):148-50. PubMed ID: 12717436
[TBL] [Abstract][Full Text] [Related]
17. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N; Doisaki S; Kojima S
Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
[TBL] [Abstract][Full Text] [Related]
18. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia.
Hasegawa D; Manabe A; Kubota T; Kawasaki H; Hirose I; Ohtsuka Y; Tsuruta T; Ebihara Y; Goto Y; Zhao XY; Sakashita K; Koike K; Isomura M; Kojima S; Hoshika A; Tsuji K; Nakahata T
Br J Haematol; 2005 Mar; 128(6):805-12. PubMed ID: 15755284
[TBL] [Abstract][Full Text] [Related]
19. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
Lauchle JO; Braun BS; Loh ML; Shannon K
Pediatr Blood Cancer; 2006 May; 46(5):579-85. PubMed ID: 16261595
[TBL] [Abstract][Full Text] [Related]
20. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
